Peptide Based Metabolic Disorders Therapeutics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022

  • Published : Aug-2017
  • Tables : 145
  • Figures : 45
  • Category : Healthcare
  • No. of Pages : 170
  • Report Code : FACT187MR
  • Format : ppt

There are several ongoing research activities and technological developments in accordance with medical research activities which focus on treatment of various ailments. Peptide therapeutics are used to treat several of these ailments, of which metabolic disorders are one type. Peptides possess good stability, efficacy, safety, and moreover, they are small in size, and hence can be easily synchronized. These advantages fuel the growth of the global peptide based metabolic disorders therapeutics market. To support the growth, factors such as technological advancements and increased funding in healthcare, and the impressive business growth of biotech and pharmaceutical companies, have spurred the adoption of the peptides used to treat metabolic disorders. Such disorders have risen, and this has called for a rapid development of therapies based on peptides to treat such disorders. North America is anticipated to show higher attractiveness in the global peptide based metabolic disorders therapeutics market.

A metabolic disorder is a disorder which can occur due to alterations in the normal metabolic processes in the body caused by abnormal chemical reactions take place within. Peptide therapeutics are used to treat metabolic disorders owing to their stability, efficiency, safety as well as tolerability. Due to their broad range of mechanisms and activities, they can be used in the treatment of metabolic disorders.

According to Fact.MR’s research report on the global peptide based metabolic disorders therapeutics market, the market is anticipated to show a robust growth rate during the forecasted period of 2017-2022 and expected to reflect a value more than US$ 8 Bn.

Market Taxonomy

Drug

Distribution Channel

Liraglutide

Hospital Pharmacies

Exenatide

Retail Pharmacies

Others

Online Pharmacies

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

North America Domination in the Peptide Based Metabolic Disorders Therapeutics

With respect to the global peptide based metabolic disorders therapeutics market, according to the market observation in 2016 and 2017, the region of North America is expected to dominate the global market in terms of higher market share. In terms of  revenues, North America is poised to grow at a higher growth rate, registering a CAGR of 10.6% throughout the period of forecast of 2017 to 2022. This region is expected to show the highest market attractiveness index, and is the most lucrative region for the growth of the global peptide based metabolic disorders therapeutics market. Middle East and Africa (MEA) and Latin America regions will show slower growth rate as compared to North America, as well as a comparatively low market revenue share

APEJ Shows a Similar Growth Rate

The Asia-Pacific excluding Japan (APEJ) region had shown rapid growth in the past with respect to global peptide based metabolic disorders therapeutics market, and is poised to reflect a higher growth rate, as fast as North America. APEJ will register a CAGR of 10.5% during the forecast period. The main reasons for this kind of growth is the strict government regulations for the upcoming players, higher number of pharmaceutical companies, increased foreign direct investment and development of technologies. Moreover, the government encourages to increase the investment in the healthcare industry to discover and invent new methods & technologies to better the health of the patients and enhance treatment outcomes. Europe region, following APEJ region, also reflects itself as a positive platform for the growth of the global peptide based metabolic disorders therapeutics market.

Liraglutide Dominates the Drug Class Category

The liraglutide segment by drug class reflects a higher market share by revenue and dominates the global market by drug class. The market share of this segment is more than two and a half times than that of the exenatide segment as of 2017. However, it is anticipated that this segment will lose BPS by the end of 2022. The growth of liraglutide segment is slow as compared to the growth rates of the exenatide and others segments throughout the period of forecast.

Exenatide and Others Segments Have a Tie

The exenatide and others segments by drug class show similar growth rate and hence can be said to congruently move along during the period of forecast. However, the exenatide segment enjoys a higher market share than the others segment, more than three times than that of the others segment during 2017 and this trend is expected to run its course throughout the period of forecast. Both these segments are expected to show a gain in the BPS by the end of 2022.

Hospital Pharmacies Segment Shows Supremacy, Online Pharmacy Shows Growth

The hospital pharmacies segment by distribution channel reflect a higher market share by revenue and a higher growth rate throughout the period of forecast. However, the online pharmacies segment shows even higher growth rate as compared to hospital pharmacies segment, and is expected to register a CAGR of 11.8% during the period of forecast. But the market share of this segment is less; hospital pharmacies segment enjoys a market share more than three times than that of online pharmacies segment. The online pharmacies segment is expected to enjoy a gain in the BPS by the end of 2022. On the other hand, the retail pharmacies segment shows moderate growth rate, yet higher than that of the hospital pharmacies segment and a market share more than double than that of the online pharmacies segment as of 2017.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of the global peptide based metabolic disorders therapeutics market through 2022, which include AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Novo Nordisk A/S, Merck & Co., Inc., Ipsen S.A, Eli Lilly and Company, CordenPharma International, and Bachem Holding AG.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR            

1. Global Peptide Based Metabolic Disorders Therapeutics Market - Executive Summary

2. Global Peptide Based Metabolic Disorders Therapeutics Market Overview
2.1. Introduction
       2.1.1. Global Peptide Based Metabolic Disorders Therapeutics Market Taxonomy
       2.1.2. Global Peptide Based Metabolic Disorders Therapeutics Market Definition
2.2. Global Peptide Based Metabolic Disorders Therapeutics Market Size (US$ Mn) and Forecast, 2012-2022
       2.2.1. Global Peptide Based Metabolic Disorders Therapeutics Market Y-o-Y Growth
2.3. Global Peptide Based Metabolic Disorders Therapeutics Market Dynamics
2.4. Regulations
2.5. Supply Chain
2.6. Cost Structure
2.7. Average Pricing Analysis 
2.8. Epidemiology
2.9. Key Participants Market Presence (Intensity Map) By Region

3. Global Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast By Drug 
3.1. Global Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast By Drug, 2012-2022
       3.1.1. Liraglutide Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
                3.1.1.1. Revenue (US$ Mn) Comparison, By Region
                3.1.1.2. Market Share Comparison, By Region
                3.1.1.3. Y-o-Y growth Comparison, By Region
       3.1.2. Exenatide Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
                3.1.2.1. Revenue (US$ Mn) Comparison, By Region
                3.1.2.2. Market Share Comparison, By Region
                3.1.2.3. Y-o-Y growth Comparison, By Region
       3.1.3. Others Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
                3.1.3.1. Revenue (US$ Mn) Comparison, By Region
                3.1.3.2. Market Share Comparison, By Region
                3.1.3.3. Y-o-Y growth Comparison, By Region

4. Global Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast By Distribution Channel 
4.1. Global Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast By Distribution Channel, 2012-2022
       4.1.1. Hospital Pharmacies Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
                4.1.1.1. Revenue (US$ Mn) Comparison, By Region
                4.1.1.2. Market Share Comparison, By Region
                4.1.1.3. Y-o-Y growth Comparison, By Region
       4.1.2. Retail Pharmacies Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
                4.1.2.1. Revenue (US$ Mn) Comparison, By Region
                4.1.2.2. Market Share Comparison, By Region
                4.1.2.3. Y-o-Y growth Comparison, By Region
       4.1.3. Online Pharmacies Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
                4.1.3.1. Revenue (US$ Mn) Comparison, By Region
                4.1.3.2. Market Share Comparison, By Region
                4.1.3.3. Y-o-Y growth Comparison, By Region

5. Global Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast By Region
5.1. Global Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       5.1.1. North America Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
                5.1.1.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.2. Latin America Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
                5.1.2.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.3. Europe Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
                5.1.3.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.4. Japan Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
                5.1.4.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.5. APEJ Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
                5.1.5.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
       5.1.6. MEA Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
                5.1.6.1. Revenue (US$ Mn) Comparison, By Drug 
                5.1.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

6. North America Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
6.1. US Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       6.1.1. Revenue (US$ Mn) Comparison, By Drug 
       6.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
6.2. Canada Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       6.2.1. Revenue (US$ Mn) Comparison, By Drug 
       6.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

7. Latin America Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
7.1. Brazil Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       7.1.1. Revenue (US$ Mn) Comparison, By Drug 
       7.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
7.2. Mexico Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       7.2.1. Revenue (US$ Mn) Comparison, By Drug 
       7.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
7.3. Argentina Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       7.3.1. Revenue (US$ Mn) Comparison, By Drug 
       7.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

8. Europe Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
8.1. Germany Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       8.1.1. Revenue (US$ Mn) Comparison, By Drug 
       8.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.2. UK Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       8.2.1. Revenue (US$ Mn) Comparison, By Drug 
       8.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.3. France Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       8.3.1. Revenue (US$ Mn) Comparison, By Drug 
       8.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.4. Spain Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       8.4.1. Revenue (US$ Mn) Comparison, By Drug 
       8.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.5. Italy Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       8.5.1. Revenue (US$ Mn) Comparison, By Drug 
       8.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
8.6. Nordic Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       8.6.1. Revenue (US$ Mn) Comparison, By Drug 
       8.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

9. Japan Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
9.1. Japan  Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       9.1.1. Revenue (US$ Mn) Comparison, By Drug 
       9.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

10. APEJ Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
10.1. China Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       10.1.1. Revenue (US$ Mn) Comparison, By Drug 
       10.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.2. India Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       10.2.1. Revenue (US$ Mn) Comparison, By Drug 
       10.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.3. Malaysia Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       10.3.1. Revenue (US$ Mn) Comparison, By Drug 
       10.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.4. Thailand Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       10.4.1. Revenue (US$ Mn) Comparison, By Drug 
       10.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.5. Singapore Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       10.5.1. Revenue (US$ Mn) Comparison, By Drug 
       10.5.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
10.6. Australia Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       10.6.1. Revenue (US$ Mn) Comparison, By Drug 
       10.6.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

11. MEA Peptide Based Metabolic Disorders Therapeutics Market Analysis and Forecast, By Country, 2012-2022
11.1. GCC Countries Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       11.1.1. Revenue (US$ Mn) Comparison, By Drug 
       11.1.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
11.2. South Africa Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       11.2.1. Revenue (US$ Mn) Comparison, By Drug 
       11.2.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
11.3. Nigeria Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       11.3.1. Revenue (US$ Mn) Comparison, By Drug 
       11.3.2. Revenue (US$ Mn) Comparison, By Distribution Channel 
11.4. Israel Peptide Based Metabolic Disorders Therapeutics Market Size and Forecast, 2012-2022
       11.4.1. Revenue (US$ Mn) Comparison, By Drug 
       11.4.2. Revenue (US$ Mn) Comparison, By Distribution Channel 

12. Global Peptide Based Metabolic Disorders Therapeutics Market Competition Landscape and Company Profile
12.1. Company Share Analysis By Region
12.2. AstraZeneca plc
       12.2.1. Company Overview
       12.2.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
       12.2.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
       12.2.4. Key Developments
       12.2.5. SWOT Analysis
12.3. Bachem Holding AG
       12.3.1. Company Overview
       12.3.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
       12.3.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
       12.3.4. Key Developments
       12.3.5. SWOT Analysis
12.4. CordenPharma International
       12.4.1. Company Overview
       12.4.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
       12.4.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
       12.4.4. Key Developments
       12.4.5. SWOT Analysis
12.5. Eli Lilly and Company
       12.5.1. Company Overview
       12.5.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
       12.5.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
       12.5.4. Key Developments
       12.5.5. SWOT Analysis
12.6. Ipsen S.A
       12.6.1. Company Overview
       12.6.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
       12.6.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
       12.6.4. Key Developments
       12.6.5. SWOT Analysis
12.7. Merck & Co., Inc
       12.7.1. Company Overview
       12.7.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
       12.7.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
       12.7.4. Key Developments
       12.7.5. SWOT Analysis
12.8. Novo Nordisk A/S
       12.8.1. Company Overview
       12.8.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
       12.8.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
       12.8.4. Key Developments
       12.8.5. SWOT Analysis
12.9. PolyPeptide Group
       12.9.1. Company Overview
       12.9.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
       12.9.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
       12.9.4. Key Developments
       12.9.5. SWOT Analysis
12.10. Teva Pharmaceutical Industries Ltd
       12.10.1. Company Overview
       12.10.2. Peptide Based Metabolic Disorders Therapeutics Market Drug list
       12.10.3. Peptide Based Metabolic Disorders Therapeutics Market Drug Sales Data and Key Financials
       12.10.4. Key Developments
       12.10.5. SWOT Analysis

13. Research Methodology

14. Secondary and Primary Sources

15. Assumptions and Acronyms

16. Disclaimer

TABLE 1 Global Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), 2012-2016
TABLE 2 Global Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), 2017-2022
TABLE 3 Global Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn) and Y-o-Y, 2015-2022
TABLE 4 Global Liraglutide Segment Value (US$ Mn), By Region 2012-2016
TABLE 5 Global Liraglutide Segment Value (US$ Mn), By Region 2017-2022
TABLE 6 Global Liraglutide Segment Market Share, By Region 2012-2016
TABLE 7 Global Liraglutide Segment Market Share, By Region 2017-2022
TABLE 8 Global Liraglutide Segment Y-o-Y, By Region 2015-2022
TABLE 9 Global Exenatide Segment Value (US$ Mn), By Region 2012-2016
TABLE 10 Global Exenatide Segment Value (US$ Mn), By Region 2017-2022
TABLE 11 Global Exenatide Segment Market Share, By Region 2012-2016
TABLE 12 Global Exenatide Segment Market Share, By Region 2017-2022
TABLE 13 Global Exenatide Segment Y-o-Y, By Region 2015-2022
TABLE 14 Global Others Segment Value (US$ Mn), By Region 2012-2016
TABLE 15 Global Others Segment Value (US$ Mn), By Region 2017-2022
TABLE 16 Global Others Segment Market Share, By Region 2012-2016
TABLE 17 Global Others Segment Market Share, By Region 2017-2022
TABLE 18 Global Others Segment Y-o-Y, By Region 2015-2022
TABLE 19 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012-2016
TABLE 20 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2017-2022
TABLE 21 Global Hospital Pharmacies Segment Market Share, By Region 2012-2016
TABLE 22 Global Hospital Pharmacies Segment Market Share, By Region 2017-2022
TABLE 23 Global Hospital Pharmacies Segment Y-o-Y, By Region 2015-2022
TABLE 24 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2016
TABLE 25 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2017-2022
TABLE 26 Global Retail Pharmacies Segment Market Share, By Region 2012-2016
TABLE 27 Global Retail Pharmacies Segment Market Share, By Region 2017-2022
TABLE 28 Global Retail Pharmacies Segment Y-o-Y, By Region 2015-2022
TABLE 29 Global Online Pharmacies Segment Value (US$ Mn), By Region 2012-2016
TABLE 30 Global Online Pharmacies Segment Value (US$ Mn), By Region 2017-2022
TABLE 31 Global Online Pharmacies Segment Market Share, By Region 2012-2016
TABLE 32 Global Online Pharmacies Segment Market Share, By Region 2017-2022
TABLE 33 Global Online Pharmacies Segment Y-o-Y, By Region 2015-2022
TABLE 34 North America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 35 North America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 36 North America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 37 North America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 38 Latin America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 39 Latin America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 40 Latin America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 41 Latin America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 42 Europe Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 43 Europe Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 44 Europe Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 45 Europe Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 46 Japan Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 47 Japan Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 48 Japan Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 49 Japan Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 50 APEJ Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 51 APEJ Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 52 APEJ Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 53 APEJ Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 54 MEA Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 55 MEA Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 56 MEA Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 57 MEA Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 58 US Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 59 US Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 60 US Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 61 US Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 62 Canada Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 63 Canada Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 64 Canada Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 65 Canada Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 66 Brazil Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 67 Brazil Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 68 Brazil Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 69 Brazil Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 70 Mexico Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 71 Mexico Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 72 Mexico Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 73 Mexico Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 74 Argentina Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 75 Argentina Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 76 Argentina Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 77 Argentina Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 78 Germany Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 79 Germany Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 80 Germany Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 81 Germany Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 82 UK Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 83 UK Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 84 UK Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 85 UK Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 86 France Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 87 France Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 88 France Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 89 France Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 90 Spain Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 91 Spain Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 92 Spain Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 93 Spain Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 94 Italy Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 95 Italy Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 96 Italy Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 97 Italy Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 98 Nordic Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 99 Nordic Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 100 Nordic Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 101 Nordic Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 102 Japan  Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 103 Japan  Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 104 Japan  Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 105 Japan  Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 106 China Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 107 China Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 108 China Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 109 China Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 110 India Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 111 India Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 112 India Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 113 India Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 114 Malaysia Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 115 Malaysia Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 116 Malaysia Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 117 Malaysia Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 118 Thailand Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 119 Thailand Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 120 Thailand Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 121 Thailand Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 122 Singapore Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 123 Singapore Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 124 Singapore Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 125 Singapore Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 126 Australia Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 127 Australia Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 128 Australia Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 129 Australia Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 130 GCC Countries Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 131 GCC Countries Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 132 GCC Countries Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 133 GCC Countries Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 134 South Africa Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 135 South Africa Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 136 South Africa Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 137 South Africa Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 138 Nigeria Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 139 Nigeria Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 140 Nigeria Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 141 Nigeria Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
TABLE 142 Israel Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
TABLE 143 Israel Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
TABLE 144 Israel Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
TABLE 145 Israel Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022

FIG. 1 Global Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), 2012-2016
FIG. 2 Global Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn) Forecast, 2017-2022
FIG. 3 Global Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn) and Y-o-Y, 2015-2022
FIG. 4 Global Liraglutide Segment Market Value (US$ Mn) By Region, 2012-2016
FIG. 5 Global Liraglutide Segment Market Value (US$ Mn) By Region, 2017-2022
FIG. 6 Global Liraglutide Segment Y-o-Y Growth Rate, By Region, 2015-2022
FIG. 7 Global Exenatide Segment Market Value (US$ Mn) By Region, 2012-2016
FIG. 8 Global Exenatide Segment Market Value (US$ Mn) By Region, 2017-2022
FIG. 9 Global Exenatide Segment Y-o-Y Growth Rate, By Region, 2015-2022
FIG. 10 Global Others Segment Market Value (US$ Mn) By Region, 2012-2016
FIG. 11 Global Others Segment Market Value (US$ Mn) By Region, 2017-2022
FIG. 12 Global Others Segment Y-o-Y Growth Rate, By Region, 2015-2022
FIG. 13 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2016
FIG. 14 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2017-2022
FIG. 15 Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2015-2022
FIG. 16 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2016
FIG. 17 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2017-2022
FIG. 18 Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2015-2022
FIG. 19 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2016
FIG. 20 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2017-2022
FIG. 21 Global Online Pharmacies Segment Y-o-Y Growth Rate, By Region, 2015-2022
FIG. 22 North America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
FIG. 23 North America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
FIG. 24 North America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
FIG. 25 North America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
FIG. 26 Latin America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
FIG. 27 Latin America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
FIG. 28 Latin America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
FIG. 29 Latin America Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
FIG. 30 Europe Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
FIG. 31 Europe Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
FIG. 32 Europe Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
FIG. 33 Europe Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
FIG. 34 Japan Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
FIG. 35 Japan Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
FIG. 36 Japan Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
FIG. 37 Japan Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
FIG. 38 APEJ Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
FIG. 39 APEJ Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
FIG. 40 APEJ Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
FIG. 41 APEJ Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022
FIG. 42 MEA Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2012-2016
FIG. 43 MEA Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Drug 2017-2022
FIG. 44 MEA Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2012-2016
FIG. 45 MEA Peptide Based Metabolic Disorders Therapeutics Market Value (US$ Mn), By Distribution Channel 2017-2022

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Benefits of Becoming a Fact.MR Client

  • Access to our global market coverage
  • Periodic updates on your sector
  • Exclusive discounts and offers
  • Greater flexibility for customization
  • Quick-research assistance for ad-hoc needs
  • Access to credible insights Fact.MR analyst interactions
  • Access to Fact.MR tools and research to fuel strategy development